Second-Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current StatusPazopanibMetastatic renal cancerVEGFTargeted therapyTyrosine kinase inhibitorIn recent years the approval of seven new agents for the treatment of metastatic renal cell carcinoma (mRCC) has dramatically improved ...
Introduction Duration of treatment with tyrosine kinase inhibitors (TKI) is an important favorable prognostic factor for treatment-free remission (TFR) and deep molecular response (DMR) in patients (pts) with chronic myeloid leukemia (CML). Aim To analyze the impact of first-line treatment duration...
In these patients, there is often an initial dramatic response to treatment with the first-generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib or gefitinib. A small number of patients with EGFR mutations have primary resistance to erlotinib and gefitinib, and most patients who initially ...
ClinicalImpactofDoseReductionsandInterruptionsofSecond-GenerationTyrosineKinaseInhibitorsinPatientswithChronicMyeloidLeukaemiaFabioPSSantos1,HagopKantarjian1,CarmenFava1,SusanO’Brien1,GuillermoGarcia-Manero1,FarhadRavandi1,WilliamWierda1,DeborahThomas1,JianquinShan1,andJorgeCortes11DepartmentofLeukemia,UniversityofTexas...
Introduction: EGFR mutant lung cancers are highly sensitive to first generation EGFR tyrosine kinase inhibitors (TKIs; gefitinib and erlotinib), but resistance eventually develops. In the majority of patients, such acquired resistance (A... K Ohashi,K Suda,S Jing,... - 《Cancer Research》 被引...
The majority of patients with chronic myeloid leukaemia (CML) respond to tyrosine kinase inhibitors (TKI), while allogeneic haematopoietic cell transplantation (HCT) is indicated in selected clinical situations. HCT carries the risk of severe complications, while the toxicity profile of dasatinib and ni...
It is unknown whether these definitions apply to patients treated with second-generation tyrosine kinase inhibitors (TKIs).One hundred sixty-seven patients with newly diagnosed chronic myelogenous leukemia (CML) in chronic phase were treated with second-generation TKIs in phase II trials (nilotinib, ...
Short-Time Second Generation Tyrosine Kinase inhibitors Combined With Allogeneic Stem Cell Transplantation for Patients with Imatinib-refractory CML,Bone marrow transplant center, 1st Affiliated Hospital, Zhejiang University,Observational,Not Applicable
Studies have shown that patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML) have improved responses with second-generation tyrosine kinase inhibitors (TKIs) compared with first-generation TKIs. A 5-year analysis of DASISION, a randomized phase III study of dasatinib (Sprycel) ...
Secondary imatinib resistance in chronic myeloid leukemia (CML) is associated in approximately 50% of cases with mutations in the BCR-ABL kinase domain, necessitating switch to one of several new tyrosine kinase inhibitors (TKIs) that act differentially on mutated BCR-ABL. We assess here whether ...